Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J.
PMID: 33975862
Clin Cancer Res. 2021 Sep 01;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11.

PURPOSE: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.PATIENTS AND METHODS: Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of...

Cite
Kim ST, Smith SA, Mortimer P, et al. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clin Cancer Res. 2021;27(17):4700-4709doi: 10.1158/1078-0432.CCR-21-0251.
Kim, S. T., Smith, S. A., Mortimer, P., Loembé, A. B., Cho, H., Kim, K. M., Smith, C., Willis, S., Irurzun-Arana, I., Berges, A., Hong, J. Y., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kozarewa, I., Pierce, A. J., Dean, E., & Lee, J. (2021). Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4700-4709. https://doi.org/10.1158/1078-0432.CCR-21-0251
Kim, Seung Tae, et al. "Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4700-4709. doi: https://doi.org/10.1158/1078-0432.CCR-21-0251
Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clin Cancer Res. 2021 Sep 01;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11. PMID: 33975862.
Copy Download .nbib Format: NLM
The Influence of Manganese on Growth Processes of .

Plants (Basel, Switzerland)

Tkachenko K, Kosareva I, Frontasyeva M.
PMID: 34069349
Plants (Basel). 2021 May 19;10(5). doi: 10.3390/plants10051009.

Manganese, as one of the xenobionts, belongs to the group of heavy metals, which, in high concentrations, can negatively affect the development of plants. In small concentrations, it is necessary for plants for normal growth and development. It is...

Cite
Tkachenko K, Kosareva I, Frontasyeva M. The Influence of Manganese on Growth Processes of . Plants (Basel). 2021;10(5)doi: 10.3390/plants10051009.
Tkachenko, K., Kosareva, I., & Frontasyeva, M. (2021). The Influence of Manganese on Growth Processes of . Plants (Basel, Switzerland), 10(5), . https://doi.org/10.3390/plants10051009
Tkachenko, Kirill, et al. "The Influence of Manganese on Growth Processes of ." Plants (Basel, Switzerland) vol. 10,5 (2021). doi: https://doi.org/10.3390/plants10051009
Tkachenko K, Kosareva I, Frontasyeva M. The Influence of Manganese on Growth Processes of . Plants (Basel). 2021 May 19;10(5). doi: 10.3390/plants10051009. PMID: 34069349; PMCID: PMC8158762.
Copy Download .nbib Format: NLM
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.

Cancers

Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC.
PMID: 34830984
Cancers (Basel). 2021 Nov 20;13(22). doi: 10.3390/cancers13225830.

BACKGROUND: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical data have suggested the potential for a combined effect...

Cite
Carr TH, Adelman C, Barnicle A, et al. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers (Basel). 2021;13(22)doi: 10.3390/cancers13225830.
Carr, T. H., Adelman, C., Barnicle, A., Kozarewa, I., Luke, S., Lai, Z., Hollis, S., Dougherty, B., Harrington, E. A., Kang, J., Saad, F., Sala, N., Thiery-Vuillemin, A., Clarke, N. W., Hodgson, D., & Barrett, J. C. (2021). Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers, 13(22), . https://doi.org/10.3390/cancers13225830
Carr, T Hedley, et al. "Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer." Cancers vol. 13,22 (2021). doi: https://doi.org/10.3390/cancers13225830
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers (Basel). 2021 Nov 20;13(22). doi: 10.3390/cancers13225830. PMID: 34830984; PMCID: PMC8616430.
Copy Download .nbib Format: NLM
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J.
PMID: 33975862
Clin Cancer Res. 2021 Sep 01;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11.

PURPOSE: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.PATIENTS AND METHODS: Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of...

Cite
Kim ST, Smith SA, Mortimer P, et al. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clin Cancer Res. 2021;27(17):4700-4709doi: 10.1158/1078-0432.CCR-21-0251.
Kim, S. T., Smith, S. A., Mortimer, P., Loembé, A. B., Cho, H., Kim, K. M., Smith, C., Willis, S., Irurzun-Arana, I., Berges, A., Hong, J. Y., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kozarewa, I., Pierce, A. J., Dean, E., & Lee, J. (2021). Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4700-4709. https://doi.org/10.1158/1078-0432.CCR-21-0251
Kim, Seung Tae, et al. "Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4700-4709. doi: https://doi.org/10.1158/1078-0432.CCR-21-0251
Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clin Cancer Res. 2021 Sep 01;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11. PMID: 33975862.
Copy Download .nbib Format: NLM
Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline .

JCO precision oncology

Kingston B, Bailleux C, Delaloge S, Schiavon G, Scott V, Lacroix-Triki M, Carr TH, Kozarewa I, Gevensleben H, Kemp Z, Pearson A, Turner N, André F.
PMID: 32923864
JCO Precis Oncol. 2019 Dec 05;3. doi: 10.1200/PO.19.00130. eCollection 2019.

No abstract available.

Cite
Kingston B, Bailleux C, Delaloge S, et al. Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline . JCO Precis Oncol. 2019;3doi: 10.1200/PO.19.00130.
Kingston, B., Bailleux, C., Delaloge, S., Schiavon, G., Scott, V., Lacroix-Triki, M., Carr, T. H., Kozarewa, I., Gevensleben, H., Kemp, Z., Pearson, A., Turner, N., & André, F. (2019). Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline . JCO precision oncology, 3. https://doi.org/10.1200/PO.19.00130
Kingston, Belinda, et al. "Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline ." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.19.00130
Kingston B, Bailleux C, Delaloge S, Schiavon G, Scott V, Lacroix-Triki M, Carr TH, Kozarewa I, Gevensleben H, Kemp Z, Pearson A, Turner N, André F. Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline . JCO Precis Oncol. 2019 Dec 05;3. doi: 10.1200/PO.19.00130. eCollection 2019. PMID: 32923864; PMCID: PMC7446515.
Copy Download .nbib Format: NLM
Author Correction: A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types.

Nature

Kozareva V, Martin C, Osorno T, Rudolph S, Guo C, Vanderburg C, Nadaf N, Regev A, Regehr WG, Macosko E.
PMID: 35022615
Nature. 2022 Jan 12; doi: 10.1038/s41586-021-04373-7. Epub 2022 Jan 12.

No abstract available.

Cite
Kozareva V, Martin C, Osorno T, et al. Author Correction: A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types. Nature. 2022;doi: 10.1038/s41586-021-04373-7.
Kozareva, V., Martin, C., Osorno, T., Rudolph, S., Guo, C., Vanderburg, C., Nadaf, N., Regev, A., Regehr, W. G., & Macosko, E. (2022). Author Correction: A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types. Nature, . https://doi.org/10.1038/s41586-021-04373-7
Kozareva, Velina, et al. "Author Correction: A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types." Nature vol. (2022). doi: https://doi.org/10.1038/s41586-021-04373-7
Kozareva V, Martin C, Osorno T, Rudolph S, Guo C, Vanderburg C, Nadaf N, Regev A, Regehr WG, Macosko E. Author Correction: A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types. Nature. 2022 Jan 12; doi: 10.1038/s41586-021-04373-7. Epub 2022 Jan 12. PMID: 35022615.
Copy Download .nbib Format: NLM
Cascade screening for glaucoma in high-risk family members of African-Caribbean glaucoma patients in an urban population in London.

The British journal of ophthalmology

Nagar A, Myers S, Kozareva D, Simcoe M, Hammond C.
PMID: 33303425
Br J Ophthalmol. 2020 Dec 10; doi: 10.1136/bjophthalmol-2020-317373. Epub 2020 Dec 10.

BACKGROUND/AIMS: Cascade screening has been used successfully in relatives of patients with inherited cancers and other genetic diseases to identify presymptomatic disease. This study was designed to examine if this approach would be successful in a high-risk group: first-degree...

Cite
Nagar A, Myers S, Kozareva D, et al. Cascade screening for glaucoma in high-risk family members of African-Caribbean glaucoma patients in an urban population in London. Br J Ophthalmol. 2020;doi: 10.1136/bjophthalmol-2020-317373.
Nagar, A., Myers, S., Kozareva, D., Simcoe, M., & Hammond, C. (2020). Cascade screening for glaucoma in high-risk family members of African-Caribbean glaucoma patients in an urban population in London. The British journal of ophthalmology, . https://doi.org/10.1136/bjophthalmol-2020-317373
Nagar, Anindyt, et al. "Cascade screening for glaucoma in high-risk family members of African-Caribbean glaucoma patients in an urban population in London." The British journal of ophthalmology vol. (2020). doi: https://doi.org/10.1136/bjophthalmol-2020-317373
Nagar A, Myers S, Kozareva D, Simcoe M, Hammond C. Cascade screening for glaucoma in high-risk family members of African-Caribbean glaucoma patients in an urban population in London. Br J Ophthalmol. 2020 Dec 10; doi: 10.1136/bjophthalmol-2020-317373. Epub 2020 Dec 10. PMID: 33303425.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries